Inhibition of naloxone-resistant antinociception by centrally administered H2-antagonists

J Pharmacol Exp Ther. 1989 Jan;248(1):262-7.

Abstract

In order to test directly the hypothesis that brain histamine and H2-receptors mediate the naloxone-resistant footshock-induced antinociception (FSIA) elicited by 3 min of 3.5 mA, the effect of i.c.v. H2-antagonists on this response was determined. Intracerebroventricular zolantidine dimaleate produced an inhibition of the response that was both time- and dose-dependent, with no effect on base-line responses. A dose of 20 micrograms produced maximal (93%) inhibition of FSIA when given 10 min before footshock, with a calculated ID50 of 7.18 nmol. Eight additional H2-antagonists with varying structures and brain-penetrating qualities also exhibited dose-dependent inhibition of the response with no effect on base-line nociception. The potencies of these compounds for inhibition of naloxone-resistant FSIA correlated significantly (r = 0.966, P less than .001; rho = 0.980, P less than .002) with their affinities at the H2-receptor, providing strong support for the hypothesis that brain histamine and H2-receptors are important components of naloxone-resistant FSIA.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Analgesia*
  • Animals
  • Benzothiazoles
  • Brain / drug effects*
  • Dose-Response Relationship, Drug
  • Drug Resistance
  • Histamine / physiology
  • Histamine H2 Antagonists / pharmacology*
  • Male
  • Naloxone / pharmacology*
  • Phenoxypropanolamines
  • Piperidines / pharmacology*
  • Rats
  • Rats, Inbred Strains
  • Thiazoles / pharmacology*

Substances

  • Benzothiazoles
  • Histamine H2 Antagonists
  • Phenoxypropanolamines
  • Piperidines
  • Thiazoles
  • Naloxone
  • Histamine
  • zolantidine